On Tuesday, Truist Securities adjusted its stance on Biomea Fusion Inc. (NASDAQ:BMEA) stock, moving from a Buy to a Hold rating. This decision comes in the wake of a clinical hold... On Monday, H ...

Biomea Fusion (NASDAQ:BMEA) has received two analyst upgrades along with bullish comments from three other firms in the wake ...

One demographic of teachers in particular are experiencing a sharp decline and a local Detroit-based organization is working ...

GSA Capital Partners LLP lowered its stake in shares of Biomea Fusion, Inc. (NASDAQ:BMEA – Free Report) by 36.8% during the third quarter, according to the company in its most recent disclosure with ...

Biomea Fusion (BMEA) announced its presentations at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management in Singapore, 18-20 November. Biomea will showcase three oral ...

On Thursday, Biomea Fusion Inc (BMEA) stock saw a decline, ending the day at $9.37 which represents a decrease of $-0.97 or -9.38% from the prior close of $10.34. The stock opened at $10.46 and ...

Arcadium Lithium, Norwegian Cruise Line, GitLab, Chewy And Other Big Stocks Moving Higher On Wednesday FDA Removes Clinical Hold On Biomea Fusion's Early-Stage Trials For Potential Diabetes ...

Oppenheimer analyst Matthew Biegler maintained a Buy rating on Biomea Fusion (BMEA – Research Report) today and set a price target of $60.00. The company’s shares closed yesterday at $10.34.

Biomea Fusion, Inc. (NASDAQ:BMEA – Get Free Report) has received an average rating of “Moderate Buy” from the eleven research firms that are covering the company, Marketbeat Ratings reports.

REDWOOD CITY, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...